Lobbying Filing Details

Total Spending

$530,000

Activities

5

Lobbyists

6

Gov't Entities

13

Filing Information
Filing UUID:
0f0b3377-e797-48a8-b699-69fa5a758241
Type:
Q3 - 3rd Quarter - Report
Period:
2024 - 3rd Quarter (July 1 - Sep 30)
Date Posted:
October 17, 2024 at 6:11 PM
Income:
$0
Expenses:
$530,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

FDA Funding.

Lobbyists (4)
  • KARIN HESSLER
  • PETER KELBEL
  • ILHAAM JAFFER
  • KELBEL RAAB (NAME ERROR)
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Copyright/Patent/Trademark

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patent Eligibility Restoration Act. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.4878: The Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act. H.R.8134: Restoring Americas Leadership In Innovation Act of 2024. H.R.9221/S.4840: Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024.

Lobbyists (5)
  • CRAIG BURTON
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

Medicare Part D Reform. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. H.R.1352/S.3934: Increasing Access to Biosimilars Act of 2023. Medicare Rebate Penalty.

Lobbyists (5)
  • CRAIG BURTON
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
Government Entities (3)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Centers For Medicare and Medicaid Services (CMS)
Activity 4
Pharmacy

Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. S.1961: Pharmaceutical Supply Chain Risk Assessment Act of 2023. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. S.2362 - Drug Shortage Prevention Act. S.2305: Biosimilar Red Tape Elimination Act. FDA Inspections. Drug-Device Combination Products. Third Party Drug Quality Studies. H.R.1503/S.2916: Prescription Information Modernization Act of 2023. H.R.2880: Protecting Patients Against PBM Abuses Act.

Lobbyists (5)
  • CRAIG BURTON
  • KARIN HESSLER
  • KATHERINE RAAB
  • PETER KELBEL
  • ILHAAM JAFFER
Government Entities (4)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • Centers For Medicare and Medicaid Services (CMS)
Activity 5
Trade (domestic/foreign)

General Trade Issues. Drug Supply Chain.

Lobbyists (3)
  • KARIN HESSLER
  • KATHERINE RAAB
  • ILHAAM JAFFER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.